Stay updated on Pembrolizumab in Neuroendocrine Tumors Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Neuroendocrine Tumors Clinical Trial page.

Latest updates to the Pembrolizumab in Neuroendocrine Tumors Clinical Trial page
- CheckyesterdayChange DetectedRevision: v3.6.5 was added, replacing the previous v3.6.4 on the page. This signals a minor platform update without changing the study's content or data presented.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe page now shows an updated revision tag: v3.6.4, replacing the previous v3.6.3. This represents a small internal update and does not alter visible study information.SummaryDifference0.1%

- Check22 days agoNo Change Detected
- Check36 days agoChange DetectedUpdated the page revision from v3.6.2 to v3.6.3, a minor platform update that does not change the displayed study details.SummaryDifference0.1%

- Check44 days agoChange DetectedThe page now shows Revision: v3.6.2, replacing the previous v3.6.0 label. This indicates a minor software update to the page's versioning without altering the study content.SummaryDifference0.1%

- Check58 days agoChange DetectedNew navigation/help sections were added (How to Read a Study Record, Common Questions, How to Join a Study) and the recruitment status was updated to No longer looking for participants; the edition label updated to Revision: v3.6.0 and the Intervention/Treatment heading formatting was standardized.SummaryDifference0.5%

- Check65 days agoChange DetectedThe page's revision tag was updated from v3.5.4 to v3.5.5, signaling an updated version of the page rendering. This does not reflect changes to the study details or content.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in Neuroendocrine Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Neuroendocrine Tumors Clinical Trial page.